Children with FH who sustain a lifelong reduction in LDL-C with LLT have a lower risk of cardiovascular disease.1,2,4 In this cohort study, substantial reductions in LDL-C among children and adolescents taking rosuvastatin were not accompanied by increased fasting glucose, fasting insulin, HOMA-IR, and HbA1c levels after 7 months. The gene discussed is INS; the disease is cardiovascular disorder.